Prime Medicine, Inc. Common Stock(PRME)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

PRME iron condor setups PRME expected move PRME IV rank history PRME Fibonacci levels PRME insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

PRME $2.90 —
Snapshot
$2.90
After hours $2.95 +1.72%
52-Week Range
$2.67 – $6.94
YTD
-17.85%
IV Rank (30D)
76.04
Straddle Price
$0.55
P/C Vol Ratio
1.16
Market Cap
$0.6B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY2.09
Cost of Equity (CAPM)16.45% (VRP-adj)
WACC16.16%
Volatility Risk Premium+127.3pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-5.8%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-472.0%
Book / Price7.8%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-3850.9%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$3.24 (Market Anchor value)
SMA 20 / Bollinger Mid$3.38
Bollinger Width / SMA20855.3% (drives anchor stability)
Net Debt$-0.0B
Market Cap$1B
Peers used for multiples: BEAM, CDNA, CRSP, GH, LLY, NTRA, PSNL, TWST
Model Conviction
98%
20-Day Fair Value
≈ by Oct 26, 2026
$2.98
α +2.7% rank 58%
40-Day Fair Value
≈ by Nov 24, 2026
$3.38
α +16.5% rank 59%
60-Day Fair Value
≈ by Dec 23, 2026
$3.73
α +28.7% rank 63%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $1.78 50% median 7.4× · 7 peers
Peer P/S $0.50 50% median 20.4× · 8 peers
Market Anchor (SMA50) $3.24 0% stability 0% (BB-width)
Options Expected (B-L 30d) $2.76 0% 5 strikes · skew +1.11
As of 2026-09-25 · updated
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$0.6B

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin def…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -6.85% 4
Feb +14.37% 4
Mar -21.78% 4
Apr -4.69% 4
May -1.14% 4
Jun +23.13% 4
Jul +11.10% 4
Aug -3.97% 4
Sep +1.98% 4
Oct -2.66% 4
Nov -8.89% 4
Dec +3.59% 4
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $3.34
SMA 50: $3.23
SMA 200: $3.51
Current: $2.94
EMA 12: $3.19
EMA 26: $3.27
MACD: -0.0722 | Signal: -0.0392
BEARISH
ADX (14): 16.24
RANGE
+DI: 26.44
−DI: 17.49

Momentum Oscillators

RSI (14): 40.91
NEUTRAL
Stoch %K: 15.20
Stoch %D: 29.20
Williams %R: -90.97

Volume & Volatility

BB Upper: $3.85
BB Lower: $2.84
NEUTRAL
OBV: 2,940,795
Vol SMA 20: 3,117,611
Vol ROC: 113.20%
ATR: $0.27
True Range: $0.56
HV 20: 72.8%
HV 30: 92.2%
HV 60: 85.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: PRME

Executive Summary: Overall assessment: BEARISH with a confidence level of 6/10 Key drivers: Bearish momentum, high volatility, negative news sentiment Primary risks: Potential technical breakdown, increased selling pressure Investment thesis: Short-term bearish trend may continue due to recent technical signals and news sentiment. Recent news sentiment impact: Negative headlines have contributed to the bearish trend.

Technical Analysis: Trend Direction: Bearish in the short-term (1-4 weeks), neutral in the medium-term (1-3 months)

Support/Resistance Levels: Upper Bollinger Band ($3.28) acts as resistance, Lower Bollinger Band ($2.85) serves as support.

Momentum Signals: RSI interpretation: 49.35 is neutral, indicating no clear buy or sell signal. MACD signal: Bearish momentum persists due to the MACD histogram being below zero (-0.09). Bollinger Bands position: The price touching the upper band indicates overbought conditions.

Volume Analysis: Volume rate of change is -14.13%, indicating decreased volume and potential selling pressure.

News & Sentiment Analysis: Recent Headlines Summary: Prime Medicine has received positive news headlines, but recent negative sentiment has dominated. Sentiment Assessment: Overall sentiment is NEUTRAL with a slight lean towards being bearish. Catalyst Identification: Upcoming investor conferences may provide some clarity on the company's future prospects.

Risk & Volatility Assessment: Beta Interpretation: Beta is 2.28, indicating high volatility relative to the market (SPY). Volatility Regime: Current volatility is above historical levels, increasing the risk. Options Market Signals: IV rank is 42.7%, suggesting medium-level volatility and some bullish sentiment.

Market Context & Positioning: Sector Performance: Biotech sector has been weak, affecting Prime Medicine's stock performance. Institutional Activity: Volume patterns suggest institutional interest is waning. Correlation Analysis: The stock moves relatively strongly with the market (R-squared = 0.33).

Key Levels & Action Items: Critical Price Levels: Support at $2.85 and resistance at $3.28. Breakout/Breakdown Levels: A break below $2.85 could signal a deeper bearish trend. Time-Sensitive Catalysts: Upcoming investor conferences may provide some clarity on the company's future prospects. Risk Management: Consider stop-loss levels around $2.90 and position sizing considerations based on recent volatility.

By analyzing the data, I conclude that Prime Medicine (PRME) is currently experiencing a short-term bearish trend driven by high volatility, negative news sentiment, and bearish momentum signals. The stock's beta is 2.28, indicating high volatility relative to the market, which increases the risk. As the company prepares for investor conferences, it may be essential to reassess the situation and adjust positions accordingly.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
48.14%
Avg Actual Move
7.01%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 After-Close 24.94% 5.70% 0.23x Within
2025-02-28 After-Close 25.79% 11.31% 0.44x Within
2025-05-08 After-Close 34.12% 1.81% 0.05x Within
2025-07-30 After-Close 33.33% 8.41% 0.25x Within
2025-11-07 Pre-Market 16.75% 11.48% 0.69x Within
2026-03-03 Pre-Market 181.82% 8.24% 0.05x Within
2026-08-06 After-Close 20.26% 2.11% 0.10x Within
Options Activity
IV Rank (30D)
76.04
IV Rank (7D)
76.04
Avg IV
205.5%
Straddle (30D)
$0.55
Straddle (7D)
$0.55
P/C Volume
1.16
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.28
Correlation (SPY)
33.6%
R²
0.11
Ann. Volatility
88.0%
SPY Volatility
13.0%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 165,895,706 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

194 filers115,109,480 shares$401.89M value69.39% of float
# Filer Shares Value % of Total % of Float Period
1 Alphabet Inc. 16,562,498 $61.12M 15.21% 9.98% 2026-06-30
2 BlackRock, Inc. Custodian 9,602,041 $35.43M 8.82% 5.79% 2026-06-30
3 ARK Investment Management LLC 8,348,746 $30.81M 7.67% 5.03% 2026-06-30
4 STATE STREET CORP (STT, STT-PG) 7,576,460 $27.96M 6.96% 4.57% 2026-06-30
5 VANGUARD GROUP INC Custodian 6,467,872 $22.44M 5.58% 3.90% 2025-12-31
6 VANGUARD CAPITAL MANAGEMENT LLC 4,522,640 $16.69M 4.15% 2.73% 2026-06-30
7 BALYASNY ASSET MANAGEMENT L.P. 3,969,082 $14.65M 3.64% 2.39% 2026-06-30
8 GOLDMAN SACHS GROUP INC Custodian 3,430,518 $12.66M 3.15% 2.07% 2026-06-30
9 Casdin Capital, LLC 3,167,175 $11.69M 2.91% 1.91% 2026-06-30
10 Woodline Partners LP 3,003,904 $11.08M 2.76% 1.81% 2026-06-30
11 UBS Group AG Custodian 2,794,689 $10.31M 2.57% 1.68% 2026-06-30
12 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,712,446 $10.01M 2.49% 1.64% 2026-06-30
13 MWG Management Ltd. 1,792,210 $9.93M 2.47% 1.08% 2025-09-30
14 Sumitomo Mitsui Trust Group, Inc. 2,412,984 $8.90M 2.22% 1.45% 2026-06-30
15 Amova Asset Management Americas, Inc. 2,407,018 $8.86M 2.20% 1.45% 2026-06-30
16 CITADEL ADVISORS LLC Custodian 2,054,543 $7.58M 1.89% 1.24% 2026-06-30
17 ADAR1 Capital Management, LLC 1,997,552 $7.37M 1.83% 1.20% 2026-06-30
18 FMR LLC Custodian 1,761,884 $6.50M 1.62% 1.06% 2026-06-30
19 MWG Caph Ltd 1,792,210 $6.22M 1.55% 1.08% 2025-12-31
20 TWO SIGMA INVESTMENTS, LP Custodian 1,524,511 $5.63M 1.40% 0.92% 2026-06-30
21 Redmile Group, LLC 1,389,632 $5.13M 1.28% 0.84% 2026-06-30
22 Jump Financial, LLC 1,240,429 $4.58M 1.14% 0.75% 2026-06-30
23 BANK OF AMERICA CORP /DE/ Custodian 981,335 $3.62M 0.90% 0.59% 2026-06-30
24 VANGUARD PORTFOLIO MANAGEMENT LLC 961,826 $3.55M 0.88% 0.58% 2026-06-30
25 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 927,538 $3.42M 0.85% 0.56% 2026-06-30
5 filers$2.84M notional
# Filer Notional Value % of Total Period
1 SIMPLEX TRADING, LLC Custodian $724.72K 25.49% 2026-06-30
2 JANE STREET GROUP, LLC Custodian $718.07K 25.25% 2026-06-30
3 CITADEL ADVISORS LLC Custodian $591.14K 20.79% 2026-06-30
4 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $495.20K 17.41% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $314.39K 11.06% 2026-06-30
5 filers$2.85M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $1.64M 57.45% 2026-06-30
2 CITADEL ADVISORS LLC Custodian $511.80K 17.98% 2026-06-30
3 JANE STREET GROUP, LLC Custodian $285.61K 10.04% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $213.28K 7.49% 2026-06-30
5 SIMPLEX TRADING, LLC Custodian $200.37K 7.04% 2026-06-30
Insider Activity
Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-08 David P Schenkein Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Thomas Cahill Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Wendy Chung Director Grant (A) +75,000 opt — EDGAR
2026-06-08 ROBERT NELSEN Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Jeffrey D Marrazzo Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Kaye I Foster-Cheek Director Grant (A) +75,000 opt — EDGAR
2026-06-08 Michael Aaron Kelly Director Grant (A) +75,000 opt — EDGAR
2026-04-17 Svetlana Ni Makhni Chief Financial Officer Grant (A) +800,000 opt — EDGAR
2026-02-27 Allan Reine Chief Executive Officer Grant (A) +1,300,000 opt — EDGAR
2026-02-24 ANN L. LEE Chief Technical Officer Grant (A) +375,000 opt — EDGAR
2026-02-24 Carman Alenson See Remarks Grant (A) +140,000 opt — EDGAR
2025-08-05 ROBERT NELSEN Director Mixed — — EDGAR
2025-08-05 Michael Aaron Kelly Director Mixed — — EDGAR
2025-08-05 David P Schenkein Director Mixed — — EDGAR
2025-08-05 Allan Reine Chief Executive Officer Mixed — — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
18 insiders · @ $2.94
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David R. Liu 10%+ Owner 20,240,945 $59.61M $163.0K 7 2025-07-01
2 GV 2019 GP, L.L.C. 10%+ Owner 10,557,092 $31.09M -$13.23M 1 2023-05-24
3 GV 2021 GP, L.L.C. 10%+ Owner 10,318,420 $30.39M -$29.07M 5 2023-06-09
4 Alphabet Inc. 10%+ Owner 10,229,657 $30.13M -$17.02M 2 2023-06-15
5 ARCH Venture Fund XII, L.P. 10%+ Owner 6,230,300 $18.35M $30.00M 1 2025-08-01
6 ARCH Venture Partners X, LLC 10%+ Owner 6,230,300 $18.35M $80.00M 1 2025-08-01
7 ARCH Venture Partners XII, L.P. 10%+ Owner 6,128,297 $18.05M $60.00M 1 2024-02-20
8 ARCH Venture Fund X, L.P. 10%+ Owner 6,128,297 $18.05M $108.80M 1 2022-10-26
9 Kristina Burow 10%+ Owner 6,128,297 $18.05M $160.00M 1 2024-02-20
10 ROBERT NELSEN Director 6,128,297 $18.05M $43.60M 8 2026-06-08
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2023-06-20
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-06-20 Alphabet Holdings LLC 10% Stockholder 522,561 $7.79M 2023-06-20 Raymond James & Associates, Inc. — EDGAR
2023-06-12 Alphabet Holdings LLC 10% Stockholder 159,596 $2.31M 2023-06-12 RAYMOND JAMES & ASSOCIATES — EDGAR
2023-06-05 Alphabet Holdings LLC 10% Stockholder 88,081 $1.42M 2023-06-05 Raymond James & Associates, Inc. — EDGAR
2023-05-30 Alphabet Holdings LLC 10% Stockholder 71,263 $974.2K 2023-05-30 Raymond James & Associates — EDGAR
2023-05-18 Alphabet Holdings LLC 10% Stockholder 260,156 $3.39M 2023-05-18 RAYMOND JAMES & ASSOCIATES INC 10b5-1 EDGAR
2023-05-08 GV 2019, L.P. 10% Stockholder 1,121,197 $16.06M 2023-05-08 RAYMOND JAMES & ASSOCIATES INC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio14.3
P/S Ratio139.4
EV/EBITDA-2.8
TTM Revenue$0.0B
TTM Net Income$-0.2B
TTM EPS$-1.08
ROE-472.0%